Mengxing Xue

机构：Soochow University, First Affiliated Hospital of Soochow University

发表论文 25 篇 · 总被引 157 次 · h-index 8

代表论文

• Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials (2020 · Blood · 被引 27)
• Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts (2019 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 22)
• Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial (2024 · Journal of Hematology & Oncology · 被引 17)
• Low‐dose cytarabine and aclarubicin combined with granulocyte colony‐stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients (2013 · Hematological Oncology · 被引 16)
• The Role of Interleukin-15 Polymorphisms in Adult Acute Lymphoblastic Leukemia (2010 · PLoS ONE · 被引 16)
• Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation (2022 · Blood · 被引 11)